Cullinan Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Cullinan Therapeutics Reports 2024 Results, Highlights Clinical Milestones and Pipeline Advancement
Cullinan Therapeutics' 2024 10-K filing highlights clinical progress across its immunology and oncology pipeline, including key milestones for CLN-978, CLN-619, and zipalertinib.
NASDAQ
Cullinan Oncology's 10-K filing highlights a diverse pipeline of oncology therapies and a strong financial position to support ongoing development.